Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2020

View Archived Issues

Bayer presents data from the phase II FOXTROT study of osocimab

First-in-human data for NEO-201 in chemoresistant solid tumors

NHP model of Ebola virus infection via mucosal challenge

CureVac and CEPI collaborate to develop vaccine against coronavirus nCoV-2019

Follicum receives grant to study binding of FOL peptides to pancreatic cell receptors

Promising results presented for leronlimab in patients with breast cancer

Vaccitech presents data from the FLU009 phase II study of its VTP-100 vaccine

Adapting NGS for coronavirus surveillance

Long QT genes mostly short on evidence

Immunotherapy combination shows promise in NSCLC

Preclinical data lead to clinical study of in derazantinib in advanced gastric cancer

Exelixis presents phase Ib data for XL-888 plus pembrolizumab in advanced gastrointestinal cancer

Voronoi patents new protein kinase inhibitors

GlaxoSmithKline discloses CREB2 inhibitors

Gilead Sciences describes new IRAK-4 inhibitors

Rodin Therapeutics divulges HDAC inhibitors

Eli Lilly and Company presents SERD inducers for cancer

DB-020 prevents cisplatin-induced hearing loss in animal model, enters clinical trial

Calibr begins first-in-human study of CCW-702 in metastatic castration-resistant prostate cancer

Eisai initiates phase II study of E-7090 in advanced cholangiocarcinoma with FGFR2 gene fusion

Researchers develop an animal model of Marburg virus infection

Gilead provides remdesivir for use in response to novel coronavirus

FDA approves Palforzia oral immunotherapy for peanut allergy

Corvus offers new data from ongoing phase I/Ib trial of CPI-818 in advanced T-cell lymphomas

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...